Iambic Therapeutics
Iambic’s AI-Designed HER2 Inhibitor IAM1363 Shows Early Anti-Tumor Activity in Heavily Pretreated Patients
Iambic Therapeutics; AI-designed drug; IAM1363; HER2 inhibitor; cancer; clinical trial; Phase 1/1b; ESMO 2025; brain-penetrant; tyrosine kinase inhibitor
Revolution Medicines and Iambic Announce $25M AI-Powered Drug Discovery Collaboration
Revolution Medicines; Iambic Therapeutics; AI drug discovery; NeuralPLexer; PropANE; oncology; RAS-addicted cancers; collaboration; pharmaceutical industry; milestone payments